Navidea Biopharmaceuticals, Inc. (NAVB) financial statements (2021 and earlier)

Company profile

Business Address 4995 BRADENTON AVENUE
DUBLIN, OH 43017
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13527533
Cash and cash equivalents13327533
Short-term investments  2    
Inventory, net of allowances, customer advances and progress billings  (0)1112
Inventory  (0)1112
Prepaid expense   0   
Prepaid expense and other current assets1
Other undisclosed current assets2297521
Total current assets:36141113937
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment0001232
Intangible assets, net (including goodwill)0000000
Intangible assets, net (excluding goodwill)0000000
Deferred costs     01
Other noncurrent assets111000 
Prepaid expense and other noncurrent assets1
Other undisclosed noncurrent assets  5  0(1)
Total noncurrent assets:1172233
TOTAL ASSETS:472112151240
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2228334
Accounts payable1017212
Accrued liabilities000000 
Employee-related liabilities1211111
Debt10252044
Restructuring reserve     0
Estimated litigation liability  3    
Disposal group, including discontinued operation  0    
Deferred revenue and credits 21  
Other undisclosed current liabilities1117224
Total current liabilities:438706911
Noncurrent Liabilities
Long-term debt and lease obligation1  10613024
Long-term debt, excluding current maturities   10613024
Operating lease, liability1
Liabilities, other than long-term debt1001232
Deferred revenue and credits 00  
Deferred revenue1
Other liabilities 001232
Other undisclosed noncurrent liabilities 11   8
Total noncurrent liabilities:11110633333
Total liabilities:55980694244
Stockholders' equity
Stockholders' equity attributable to parent(2)211(68)(54)(30)(4)
Preferred stock     00
Common stock0000000
Common stock, value, subscriptions0     
Additional paid in capital346338331327326323313
Accumulated other comprehensive loss (0)(0)    
Accumulated deficit(348)(337)(320)(395)(381)(353)(317)
Stockholders' equity attributable to noncontrolling interest11100  
Total stockholders' equity:(1)212(68)(54)(30)(4)
TOTAL LIABILITIES AND EQUITY:472112151240

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues112221361
Revenue, net0191141
Sublease income0
Cost of revenue(0)(0)(0)(2)(2)(2)(0)
Cost of goods and services sold  (0)(2)(2)(2)(0)
Other undisclosed gross profit     1 
Gross profit:112201151
Operating expenses(12)(12)(16)(22)(30)(32)(39)
Operating loss:(11)(11)(14)(2)(19)(28)(38)
Nonoperating income (expense)00(0)(0)0(8)(4)
Investment income, nonoperating0  (0) 00
Other nonoperating income (expense)(0)0(0)(0)00(0)
Interest and debt expense(0)(5)(4)(2)(2)(6)(4)
Other undisclosed income from continuing operations before equity method investments, income taxes      4
Loss from continuing operations before equity method investments, income taxes:(11)(16)(18)(4)(21)(42)(43)
Loss from equity method investments   (0)(0)(1) 
Other undisclosed income (loss) from continuing operations before income taxes0(0)0(10)(7)  
Loss from continuing operations before income taxes:(11)(16)(18)(14)(29)(43)(43)
Income tax expense (benefit)(0)04 0  
Loss from continuing operations:(11)(16)(14)(14)(28)(43)(43)
Income (loss) from discontinued operations(0)   1  
Loss before gain (loss) on sale of properties:(11)(16)(14)(14)(28)(43)(43)
Other undisclosed net income 089    
Net income (loss):(11)(16)75(14)(28)(43)(43)
Net income attributable to noncontrolling interest00000  
Other undisclosed net income (loss) attributable to parent   (0) 7 
Net income (loss) attributable to parent:(11)(16)75(14)(28)(36)(43)
Preferred stock dividends and other adjustments    (0)  
Other undisclosed net income available to common stockholders, basic   0   
Net income (loss) available to common stockholders, diluted:(11)(16)75(14)(28)(36)(43)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(11)(16)75(14)(28)(43)(43)
Other undisclosed comprehensive income (loss)00(0)    
Comprehensive income (loss):(11)(16)75(14)(28)(43)(43)
Comprehensive income, net of tax, attributable to noncontrolling interest00000  
Comprehensive income (loss), net of tax, attributable to parent:(11)(16)75(14)(28)(43)(43)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: